MONDAY, Oct. 28, 2024 — From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) inhibitors among individuals with type 1 diabetes (T1D), according…Original Article
2010 to 2023 Saw Increase in GLP-1 RA, SGLT2 Inhibitor Use in Type 1 Diabetes
MONDAY, Oct. 28, 2024 — From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) inhibitors among individuals with type 1 diabetes (T1D), according…
